Navigation Links
Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
Date:9/19/2013

SAN DIEGO, Sept. 19, 2013 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the BioCentury NewsMakers in the Biotech Industry conference at the Millennium Broadway Hotel in New York City on Friday, September 27, 2013.

Michael Martino, Ambit's CEO, will provide an overview of the Company and its lead drug candidate, quizartinib, at 8:30 a.m. EDT.  The presentation will be webcast live through the "Investors & Media" section of the Ambit website at www.ambitbio.com.  An audio replay will be available for 30 days following the initial presentation webcast. 

About Ambit Biosciences
Ambit is a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Ambit's lead drug candidate, quizartinib (AC220), is a once-daily, orally-administered potent and selective, inhibitor of FMS-like tyrosine kinase-3 (FLT3) and is currently under clinical development in patients with relapsed/refractory acute myeloid leukemia (AML) and in newly diagnosed AML patients in combination with chemotherapy as well as maintenance following a hematopoietic stem cell transplantation (HSCT). In addition to quizartinib, Ambit's clinical pipeline includes AC410, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva Pharmaceutical Industries Ltd. Ambit's preclinical portfolio includes a proprietary CSF1R inhibitor program.Ambit Contacts:Marcy Graham

Ian Stone/
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
2. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
3. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
4. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
5. Ambit Biosciences to Present at Two Upcoming Investor Conferences
6. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
7. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
8. Natural Skin Care Solution, Probiotic Action Announces the Use of Their Probiotic Cleanser As a Anti-Acne Body Wash
9. Creabilis Announces Treatment of First Patients in its Phase 2b Trial of CT327 in Pruritus in Atopic Dermatitis Patients
10. Neogen announces 1st quarter results conference call
11. Global Industry Analysts, Inc. Announces the Launch of a Major Research Program Analysing the Global Market for Circulating Tumor Cells and Cancer Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 Shimadzu Scientific Instruments ... multipurpose UV-visible spectrophotometer. Offering wavelength scanning from 190 ... ideal for applications in a variety of industries, ... The user-friendly UV-1280 enables intuitive operation, while the ...
(Date:1/22/2015)... NH (PRWEB) January 22, 2015 GEA ... a table top laboratory homogenizer, the PandaPLUS 2000, which ... nanodispersions, nanoemulsions , and cell disruption . This ... dairy products, fruit juices, liquid food, food additives and ...
(Date:1/22/2015)... Cambridge Semantics, the leading provider of smart data solutions ... a record-breaking year across the board for the company. ... Platform and our Smart Data solutions, our customers were able ... led to record growth for the company in 2014,” said ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Protocol Networks ... The growing team of brand-neutral, independent consultants, Protocol Networks ... Rogers explained that over the years, his company has ... Moroso, Town of Plainfield, as well as others. With ...
Breaking Biology Technology:Shimadzu’s New Monitored Single-Beam UV-Vis Spectrophotometer Offers Comprehensive Measurement Options in a Compact Body 2GEA Niro Soavi Announces the PandaPLUS 2000 Homogenizer for Processing New Applications for Nanoemulsions and Cell Disruption 2Cambridge Semantics Announces Record Results for 2014 2Protocol Networks Brings Independent Technology Consulting to the Constitution State 2
... Pharmaceuticals, Inc., a privately held drug development company, ... New Drug (IND) application with the U.S. Food ... anticancer compound. GGTI-2418 is a synthetic peptidomimetic ... to induce apoptosis by downregulating several pivotal oncogenic ...
... Advancing Core Lysosomal Storage Disorder Programs to Key Milestones ... 5 Amicus Therapeutics (Nasdaq: FOLD ) ... full year 2008. On a reported basis calculated in ... announced a net loss attributable to common stockholders of ...
... CALGARY, Feb. 5 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President ... ONCY ), will present a corporate overview ... America Conference on Monday, February 9, 2009 at 4:30 ... Westin Bayshore Resort in Vancouver, B.C. from February 8-10, ...
Cached Biology Technology:Tigris Pharmaceuticals Files IND Application for GGTI-2418 2Tigris Pharmaceuticals Files IND Application for GGTI-2418 3Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results 2Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results 3Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results 4Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results 5Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results 6Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results 7Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results 8Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results 9Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results 10Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results 11Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results 12Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results 13Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering North America 2
(Date:12/11/2014)... 09, 2014 Research and Markets , ... ) has announced the addition of the "Biometrics ... offering. One major trend emerging in ... in technology, it is important to upgrade biometric solutions ...
(Date:12/11/2014)... N.C. , Dec. 10, 2014  That blood pressure plays ... a while. Hypertension – the medical term for high blood ... early 1800s, and the inflatable cuff that,s used in measuring ... however, mean there,s nothing new about hypertension, its triggers and ...
(Date:12/10/2014)... here before: you desperately need to sign into your online banking ... to your secret question. What,s your dog,s birthday? Who was your ... a digital infrastructure security company, launches the app that ... usernames, passwords and PINs – 1U TM . 1U ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... As natural gas development expands nationwide, policymakers, communities ... impact assessments (HIA) as a means of predicting the ... new study from the Colorado School of Public Health. ... American Journal of Public Health , highlights lessons learned ...
... WHAT: ... Charitable Trusts as the "Biomedical Researcher of the Month," for his ... As a postdoctoral researcher in the Princeton University laboratory of Lynn ... type 1 (HSV-1)which, in rare cases, can lead to blindness or ...
... of the Philosophical Transactions of The Royal Society ... our society: feeding a global population that is simultaneously ... preventing widespread ecological and social impoverishment. According ... Hole Research Center (WHRC) and one of the issue,s ...
Cached Biology News:Health impact assessments prove critical public health tool 2Viral curiosity spreads across continents 2Ecology, economy and management of an agro-industrial Amazon frontier 2Ecology, economy and management of an agro-industrial Amazon frontier 3
... CultureWell cell culture chambered coverslips ... cells for staining and imaging. ... silicone gaskets with standard optical-quality ... and ready to use. Preassembled ...
... mL - 25 mL pipets ,Angled acrylic pipet ... standard square or round pipet cans. Constructed of 6 ... 76 mm W x 76 mm H x 289 ... Overall dimensions: 89 mm W x 406 mm H ...
... CultureWell cell culture systems provide an ... for staining and imaging. Each system ... standard optical-quality coverslips in cell culture ... sterile and ready to use. Individual ...
Request Info...
Biology Products: